GoodRx Holdings, Inc. (GDRX) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Medical - Healthcare Information Services
EV/EBITDA
↓
4.17
↓-94% vs avg
5yr avg: 72.26
30Y Low4.4·High34.6
P/FCF
↓
5.61
↓-83% vs avg
5yr avg: 33.82
30Y Low5.9·High116.0
P/B Ratio
↓
1.54
↓-71% vs avg
5yr avg: 5.23
30Y Low1.6·High16.1
ROE
↑
4.5%
↓+1484% vs avg
5yr avg: -0.3%
30Y Low-41%·High5%
Debt/EBITDA
↓
0.34
↓-96% vs avg
5yr avg: 8.13
30Y Low0.3·High14.6
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
GDRX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
GoodRx Holdings, Inc. trades at 31.2x earnings, 56% below its 5-year average of 71.5x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a premium of 41%. On a free-cash-flow basis, the stock trades at 5.6x P/FCF, 83% below the 5-year average of 33.8x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $922M | $967M | $1.8B | $2.7B | $1.9B | $13.4B | $11.1B | — | — |
| Enterprise Value | $720M | $765M | $1.9B | $2.8B | $1.9B | $13.2B | $10.8B | — | — |
| P/E Ratio → | 31.18 | 31.77 | 111.24 | — | — | — | — | — | — |
| P/S Ratio | 1.16 | 1.21 | 2.30 | 3.66 | 2.51 | 17.97 | 20.12 | — | — |
| P/B Ratio | 1.54 | 1.57 | 2.52 | 3.61 | 2.36 | 16.11 | 15.58 | — | — |
| P/FCF | 5.61 | 5.89 | 16.06 | 33.31 | 21.01 | 92.84 | 116.01 | — | — |
| P/OCF | 5.49 | 5.76 | 9.92 | 19.88 | 13.11 | 74.94 | 84.37 | — | — |
P/E links to full P/E history page with 30-year chart
GDRX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
GoodRx Holdings, Inc.'s enterprise value stands at 4.2x EBITDA, 94% below its 5-year average of 72.3x. The Healthcare sector median is 14.2x, placing the stock at a 71% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.96 | 2.42 | 3.72 | 2.46 | 17.65 | 19.64 | — | — |
| EV / EBITDA | 4.17 | 4.43 | 14.17 | 34.56 | 33.69 | 274.47 | — | — | — |
| EV / EBIT | 8.23 | 7.72 | 22.74 | 2411.66 | 171.07 | 977.30 | — | — | — |
| EV / FCF | — | 4.65 | 16.90 | 33.78 | 20.57 | 91.18 | 113.22 | — | — |
GDRX Profitability
Margins and return-on-capital ratios measuring operating efficiency
GoodRx Holdings, Inc. earns an operating margin of 11.0%. Operating margins have expanded from -3.6% to 11.0% over the past 3 years, signaling improving operational efficiency. ROE of 4.5% is modest. ROIC of 10.6% represents solid returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 92.8% | 92.8% | 93.9% | 91.1% | 91.5% | 93.7% | 94.6% | 96.4% | 97.6% |
| Operating Margin | 11.0% | 11.0% | 8.3% | -3.6% | 0.2% | 1.8% | -50.1% | 36.0% | 31.0% |
| Net Profit Margin | 3.8% | 3.8% | 2.1% | -1.2% | -4.3% | -3.4% | -53.3% | 17.0% | 17.6% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | 4.5% | 4.5% | 2.2% | -1.1% | -4.0% | -3.3% | -41.3% | — | — |
| ROA | 2.2% | 2.2% | 1.1% | -0.6% | -2.0% | -1.6% | -31.2% | 18.8% | 13.9% |
| ROIC | 10.6% | 10.6% | 6.1% | -2.6% | 0.2% | 1.9% | -983.6% | — | — |
| ROCE | 7.2% | 7.2% | 4.8% | -1.8% | 0.1% | 0.9% | -30.8% | 42.9% | 25.9% |
GDRX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
GoodRx Holdings, Inc. carries a Debt/EBITDA ratio of 0.3x, which is very conservative (89% below the sector average of 3.2x). The company holds a net cash position — cash of $262M exceeds total debt of $60M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns. Interest coverage of just 2.3x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.10 | 0.75 | 0.93 | 0.88 | 0.84 | 0.99 | — | — |
| Debt / EBITDA | 0.34 | 0.34 | 4.01 | 8.82 | 12.82 | 14.65 | — | 4.64 | 8.30 |
| Net Debt / Equity | — | -0.33 | 0.13 | 0.05 | -0.05 | -0.29 | -0.37 | — | — |
| Net Debt / EBITDA | -1.17 | -1.17 | 0.70 | 0.48 | -0.72 | -4.98 | — | 4.47 | 7.90 |
| Debt / FCF | — | -1.23 | 0.84 | 0.47 | -0.44 | -1.65 | -2.79 | 8.83 | 16.45 |
| Interest Coverage | 2.33 | 2.33 | 1.59 | 0.02 | 0.32 | 0.57 | -9.87 | 2.67 | 3.36 |
Net cash position: cash ($262M) exceeds total debt ($60M)
GDRX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
GoodRx Holdings, Inc.'s current ratio of 2.61x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 7.12x to 2.61x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.61 | 2.61 | 5.32 | 7.12 | 12.05 | 13.42 | 18.24 | 2.59 | 4.40 |
| Quick Ratio | 2.61 | 2.61 | 5.32 | 7.12 | 12.05 | 13.42 | 18.24 | 2.59 | 4.40 |
| Cash Ratio | 1.06 | 1.06 | 3.62 | 5.49 | 9.92 | 11.60 | 16.32 | 0.78 | 2.08 |
| Asset Turnover | — | 0.57 | 0.57 | 0.47 | 0.48 | 0.46 | 0.37 | 1.00 | 0.79 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 107.98 | 74.09 | 77.86 | 57.93 | 61.90 | 64.49 | 52.20 | 48.80 |
GDRX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
GoodRx Holdings, Inc. returns 22.4% to shareholders annually primarily through share buybacks. The earnings yield of 3.2% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | 3074.4% |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 3.2% | 3.1% | 0.9% | — | — | — | — | — | — |
| FCF Yield | 17.8% | 17.0% | 6.2% | 3.0% | 4.8% | 1.1% | 0.9% | — | — |
| Buyback Yield | 22.4% | 21.4% | 8.7% | 3.8% | 5.3% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 22.4% | 21.4% | 8.7% | 3.8% | 5.3% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $357M | $392M | $410M | $413M | $410M | $275M | $363M | $363M |
Peer Comparison
Compare GDRX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 GDRXYou | $922M | 31.2 | 4.2 | 5.6 | 92.8% | 11.0% | 4.5% | 10.6% | 0.3 |
 HIMS | $8B | 69.5 | 55.1 | 105.3 | 73.8% | 4.5% | 25.2% | 8.6% | 7.9 |
 TDOC | $1B | -7.1 | 17.1 | 5.1 | 69.5% | -10.4% | -13.9% | -11.5% | 10.4 |
 OPRX | $93M | 18.4 | 5.9 | 5.0 | 63.3% | 11.0% | 4.2% | 6.8% | 1.6 |
 PHVS | $2B | -9.7 | — | — | — | — | -65.2% | — | — |
 DOCS | $4B | 20.9 | 16.8 | — | 89.1% | 33.3% | 19.3% | 19.8% | 0.0 |
 AMWL | $141M | -1.4 | — | — | 53.3% | -42.2% | -33.9% | -95.1% | — |
 PGNY | $2B | 40.1 | 21.7 | 10.7 | 23.6% | 6.6% | 12.5% | 18.1% | 0.3 |
 CVS | $125B | 70.7 | 14.0 | 16.1 | 13.8% | 2.6% | 2.3% | 5.0% | 6.2 |
 MCK | $90B | 19.6 | 13.2 | 15.8 | 3.6% | 1.6% | — | 254.1% | 1.2 |
 CAH | $52B | 34.4 | 18.8 | 28.2 | 3.7% | 1.0% | — | 3378.7% | 3.0 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
GDRX — Frequently Asked Questions
Quick answers to the most common questions about buying GDRX stock.
What is GoodRx Holdings, Inc.'s P/E ratio?
GoodRx Holdings, Inc.'s current P/E ratio is 31.2x. The historical average is 71.5x.
What is GoodRx Holdings, Inc.'s EV/EBITDA?
GoodRx Holdings, Inc.'s current EV/EBITDA is 4.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 21.7x.
What is GoodRx Holdings, Inc.'s ROE?
GoodRx Holdings, Inc.'s return on equity (ROE) is 4.5%. The historical average is -7.2%.
Is GDRX stock overvalued?
Based on historical data, GoodRx Holdings, Inc. is trading at a P/E of 31.2x. Compare with industry peers and growth rates for a complete picture.
What are GoodRx Holdings, Inc.'s profit margins?
GoodRx Holdings, Inc. has 92.8% gross margin and 11.0% operating margin. Operating margin between 10-20% is typical for established companies.
How much debt does GoodRx Holdings, Inc. have?
GoodRx Holdings, Inc.'s Debt/EBITDA ratio is 0.3x, indicating low leverage. A ratio below 2x is generally considered financially healthy.